Dong-A ST Co., Ltd. (170900)

Overview

Dong-A ST Co., Ltd., established in 1932 and based in Seoul, South Korea, operates in the global pharmaceutical industry. It specializes in the development, manufacturing, and international marketing of pharmaceutical products. The company's portfolio encompasses a wide range of ethical drugs catered to various medical conditions and diseases. Additionally, Dong-A ST Co., Ltd. extends its offerings to include licensed drugs and high-technology medical devices, targeting a diverse segment of the healthcare and medical sector.

Products and Services

Closerin Cap: Designed for the treatment of active pulmonary and extra-pulmonary tuberculosis, aiming to address this critical infectious disease.

Dulastin PFS and Leucostim injection/PFS: These products are intended to manage neutropenia in patients who are undergoing myelosuppressive chemotherapy, helping to mitigate this common and potentially serious side effect.

Eporon inj./PFS: Focused on alleviating anemia associated with chronic renal failure, this product addresses the needs of patients suffering from this condition.

Gemcit inj.: Aims to treat various types of cancer, including non-small cell lung, pancreatic, breast, bladder, and ovarian cancers, contributing to the broader oncology therapeutic area.

Gonadopin inj./PFS: This product is utilized for treating infertility and anovulation, providing solutions for reproductive health challenges.

Growtropin II inj./AQ /cartridge: Targets growth failure due to inadequate secretion of growth hormone and idiopathic short stature, focusing on pediatric and endocrinological disorders.

Mainta inj.: Developed for the treatment of non-small cell lung cancer and malignant pleural mesothelioma, offering options for patients with these serious conditions.

Monotaxel inj.: Provides treatment options for a variety of cancers, including breast, non-small cell lung, prostate, head and neck cancers, as well as gastric adenocarcinoma, marking its significance in oncology.

Motilitone tab.: Used in the treatment of functional dyspepsia, addressing gastrointestinal disorders with this targeted therapy.

Stillen tab.: Aimed at treating gastritis, contributing to the management of gastrointestinal inflammation and discomfort.

Suganon tab./Sugamet XR tab.: These products are specifically formulated for the management of type 2 diabetes mellitus, highlighting the company's role in chronic disease management.

Terizidone tab: Another product in the lineup for treating active pulmonary and extra-pulmonary tuberculosis, reinforcing the company’s commitment to infectious disease treatment.

Zydena tab.: A solution for erectile dysfunction, addressing this common men's health issue with a targeted pharmaceutical approach.

In addition to these pharmaceutical products, Dong-A ST also engages in the provision of medical devices, including high-technology devices, custom-made products, and sets of artificial cardiac circuits for open-heart surgery, thereby broadening its impact on healthcare and patient outcomes.